Skip to main content
OpenTrials
Completed

NCT Number: NCT03771924

Postprandial Response of Individuals to Dietary Inorganic Phosphate

The study aims to compare the postprandial response of plasma phosphate and cardiometabolic relevant factors to phosphate intake in defined diet(s).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Martin-Luther-University Institute of Agriculture and Nutritional Science

Halle, Saxony-Anhalt, 06120, Germany

About this study

It is a monocentric, controlled intervention trial. The study will be carried out in cross-over design. This design was chosen because of a moderately strong individual metabolic response to the test meal.

Two interventions are planned in which the subjects will receive a test meal with phosphate supplement or with placebo in random order on 2 days. Subjects will be randomized to one of the 2 treatment arms.

On the two intervention days (T1 and T2), the subjects are placed a venous indwelling cannula. Immediately after the first blood sample the subjects take the fat and carbohydrate-rich test meal along with 700 mg of phosphorus or a placebo, both in the form of capsules. Phosphorus is administered as sodium phosphate . The placebo used is sodium chloride with equivalent amounts of sodium. The filler should be silica and mannitol. The capsules are made of hard gelatin and dissolve in about 10 minutes. The capsules are taken with 300 ml of water. The verum and placebo capsules are produced by the central pharmacy of the University Hospital.

The test meal consists of a pasta dish with oily tomato sauce. It is freshly prepared by the study staff and packaged airtight in individual portions before being handed out to the subjects. The test meal should be consumed within 10 - 12 minutes. The time is documented by the study staff. The next blood sample is taken immediately after the end of consumption (time 0), all other 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420 and 480 minutes thereafter. All blood samples are taken in a lying position. The first 3 hours after eating the test meal the subjects should spend reclining. In the following 5 hours subjects are free to move in the study center with each patient taking a recumbent position 10 minutes before the next blood draw. Immediately before all blood samples are taken the measurement of blood pressure and pulse is provided for which the opposite arm is to be used. Furthermore the collection of urine samples is provided every hour. Subjects are encouraged to take 200 ml of water every hour on the intervention day. At the end of the intervention, a snack will be provided.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • healthy men and women
  • age between 18 and 60 years
  • informed consent
  • body mass index between 18,5 up to 29,9 kg/m2
  • anamnesis without diagnostic findings

Exclusion criteria

  • Participants with epidermal growth factor receptor (eGFR) < 90 ml/min and chronic kidney disease
  • Subjects suffering from vitamin D-deficiency (plasma 25(OH)D < 30 nmol/l)
  • Pregnancy or lactation
  • Subjects with any acute or chronic diseases (infection, tumor, cardiovascular diseases, respiratory diseases, inflammatory diseases), gastrointestinal diseases, diabetes mellitus type 1 and 2, bone diseases, diseases of the parathyroid gland
  • Use of medication
  • Use of dietary supplements (minerals)
  • Relevant food allergies (wheat protein, tomatoes)
  • Weight reduction
  • Smokers
  • Blood donor in the last 3 months
  • Participation in another intervention study

Treatment and study plan

inorganic phosphate

Dietary Supplement

Sodium phosphate

Placebo

Dietary Supplement

Sodium chlorid

Primary outcomes

  1. Postprandial change of plasma phosphate concentration from baseline (0 minute) until 480 minutes

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels of plasma phosphate concentration

Secondary outcomes

  1. Postprandial course of the plasma concentration of: electrolytes (calcium, sodium, potassium, magnesium)

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels

  2. Postprandial course of the plasma concentration of: phosphate status markers (c-terminal and intact FGF23, parathormone, soluble Klotho (sKlotho), calcitriol)

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels

  3. Postprandial course of plasma concentration of: cardiovascular risk marker glucose

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels

  4. Postprandial course of plasma concentration of: cardiovascular risk marker insulin

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels

  5. Postprandial course of plasma concentration of: cardiovascular risk marker triglycerides

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels

  6. Postprandial course of plasma concentration of: cardiovascular risk marker cholesterol

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels

  7. Postprandial course of concentration of: calcification markers dephosphorylated, noncarboxylated matrix Gla protein (dp-ucMGP), fetuin A, osteocalcin, osteoprotegerin) Inflammatory markers (hsCRP and inflammatory cytokines, especially interleukin (IL-1β)

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels

  8. Activation of NLRP3-inflammasome components (ASC, caspase-1) in isolated peripheral blood monocytes (PBMC) and granulocytes under basal conditions and after stimulation

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels

  9. systolic and diastolic blood pressures

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    time course: measurement of blood pressure in mm Hg

  10. heart rate

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    time course: measurement of heart rate in beats per minute

  11. Postprandial course of urine concentrations of electrolytes (phosphate, sodium, potassium, calcium, magnesium) and creatinine

    Time frame: 0,15,30,45,60,90,120,180,240,300, 360, 420 and 480 minutes after ingestion of testmeal rich in carbohydrates and fat

    Impact of inorganic phosphate on the postprandial levels

Sponsors and collaborators

Lead sponsor

Martin-Luther-Universität Halle-Wittenberg

Other

Collaborators

  • German Federal Ministry of Education and Research

Registry information

Official study title

Postprandial Response of Individuals to Dietary Inorganic Phosphate- a Randomized Trial

Important dates

Study start
2018
Primary completion
2018
Study completion
2020
First posted
Dec 11, 2018
Registry last updated
May 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.